Naxitamab combined with granulocyte‐macrophage colony‐stimulating factor as consolidation for high‐risk neuroblastoma patients in complete remission

Naxitamab is a humanized anti‐disialoganglioside (GD2) monoclonal antibody approved for treatment of bone/bone marrow refractory high‐risk neuroblastoma (HR‐NB). Compassionate use (CU) expanded access program at Hospital Sant Joan de Deu permitted treatment of patients in complete remission (CR). We here report the survival, toxicity, and relapse pattern of patients in first or second CR treated with naxitamab and sargramostim (GM‐CSF).

[1]  J. Mora,et al.  Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma , 2021, Cancers.

[2]  A. Markham.  Naxitamab: First Approval , 2021, Drugs.

[3]  A. Naranjo,et al.  Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 , 2021, Clinical Cancer Research.

[4]  Yi Feng,et al.  Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma with Prior Disease Progression. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Mora,et al.  The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies , 2020, Frontiers in Pharmacology.

[6]  F. Berthold,et al.  Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Naranjo,et al.  Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. , 2019, JAMA.

[8]  N. Cheung,et al.  Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial , 2018, JAMA oncology.

[9]  Ruth Ladenstein,et al.  Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[10]  A. Naranjo,et al.  Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials , 2017, Cancer.

[11]  K. McHugh,et al.  Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  X. Paoletti,et al.  Outcome of children with relapsed or refractory neuroblastoma: A meta‐analysis of ITCC/SIOPEN European phase II clinical trials , 2017, Pediatric blood & cancer.

[13]  I. Ostrovnaya,et al.  Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin , 2015, Oncotarget.

[14]  I. Ostrovnaya,et al.  Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study , 2015, Oncoimmunology.

[15]  N. Cheung,et al.  Disialoganglioside GD2 as a therapeutic target for human diseases , 2015, Expert opinion on therapeutic targets.

[16]  J. Mora,et al.  Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7) , 2015, Clinical and Translational Oncology.

[17]  N. Cheung,et al.  Striking dichotomy in outcome of MYCN‐amplified neuroblastoma in the contemporary era , 2014, Cancer.

[18]  I. Ostrovnaya,et al.  Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Hong-fen Guo,et al.  Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo , 2012, Oncoimmunology.

[20]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[21]  K. Matthay,et al.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  N. Cheung,et al.  Monoclonal antibody therapies for solid tumors , 2009, Expert opinion on biological therapy.

[23]  F. Berthold,et al.  The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. , 2008, European journal of cancer.

[24]  D. Machin,et al.  High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. , 2008, The Lancet. Oncology.

[25]  N. Cheung,et al.  Disialoganglioside Directed Immunotherapy of Neuroblastoma , 2007, Cancer investigation.

[26]  F. Berthold,et al.  Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. , 2005, The Lancet. Oncology.

[27]  N. Cheung,et al.  The impact of gross total resection on local control and survival in high-risk neuroblastoma. , 2004, Journal of pediatric surgery.

[28]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[29]  Bernard Asselain,et al.  Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  N. Cheung,et al.  Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. , 1985, Cancer research.

[31]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[32]  N. Cheung,et al.  Stage IV neuroblastoma more than 1 year of age at diagnosis: major response to chemotherapy and survival durations correlated strongly with dose intensity. , 1991, Progress in clinical and biological research.